Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (681-690 of 869) with videos related to

Pageof 87
Sort By:
Blood|January 5, 2023
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myelomaMehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivoMasood A Shammas, Aamer Qazi, Ramesh B Batchu, et al.
Blood|June 4, 2026
PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple MyelomaAnaïs Schavgoulidze, Jian Cui, Jessica Encinas, et al.
Blood|March 27, 2007
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Kenji Ishitsuka, et al.
Blood|May 28, 2010
PI3K/p110{delta} is a novel therapeutic target in multiple myelomaHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Nature Communications|February 14, 2024
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myelomaJiye Liu, Lijie Xing, Jiang Li, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
Blood|September 1, 2007
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaXavier Leleu, Xiaoying Jia, Judith Runnels, et al.
British Journal of Haematology|April 26, 2014
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomideAndrew J Yee, Parameswaran Hari, Raffaella Marcheselli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation StatusMichele Cea, Antonia Cagnetta, Chirag Acharya, et al.
Pageof 87

Showing results (681-690 of 869) with videos related to

Sort By:
Pageof 87
Blood|January 5, 2023
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myelomaMehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivoMasood A Shammas, Aamer Qazi, Ramesh B Batchu, et al.
Blood|June 4, 2026
PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple MyelomaAnaïs Schavgoulidze, Jian Cui, Jessica Encinas, et al.
Blood|March 27, 2007
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Kenji Ishitsuka, et al.
Blood|May 28, 2010
PI3K/p110{delta} is a novel therapeutic target in multiple myelomaHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Nature Communications|February 14, 2024
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myelomaJiye Liu, Lijie Xing, Jiang Li, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
Blood|September 1, 2007
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaXavier Leleu, Xiaoying Jia, Judith Runnels, et al.
British Journal of Haematology|April 26, 2014
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomideAndrew J Yee, Parameswaran Hari, Raffaella Marcheselli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation StatusMichele Cea, Antonia Cagnetta, Chirag Acharya, et al.
Pageof 87